Dividend amount (per share): NOK 0.75
Declared currency: NOK
Last day including right: 22 January 2024
Ex-date: 23 January 2024
Record date: 24 January 2024
Payment date: 30 January 2024 (on or about)
Date of approval: 10 January 2024
For further information, please contact:
Alexander Karlsen
CFO
+47 97 05 36 21
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…